The startup develops a healthcare device that continuously monitors vital biological signals, including ECG, respiratory rate, and oxygen saturation, to detect early signs of sepsis and other inflammatory diseases. By providing real-time data, the device enables healthcare professionals to make timely, life-saving decisions in critical situations.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Clinical trials for mental health and inflammatory diseases face challenges due to high costs, unreliable patient selection methods, and a significant percentage of non-responders, leading to inefficient trials and delayed access to effective treatments. Current monitoring methods rely on subjective self-reporting, which can be inconsistent and prone to bias. Undetected inflammation also poses a significant risk in hospitalized patients, potentially leading to fatal conditions like sepsis.
Solution
InflammaSense offers a solution that enhances clinical trials and patient treatment through real-time, objective biomarkers. The company's technology integrates Autonomic Neurography (ANG) to monitor neural activity and in-silico analysis of saliva and blood metabolites to provide comprehensive insights into disease progression, treatment efficacy, and patient response. This dual-method approach provides continuous monitoring, improving the precision, reliability, and scalability of clinical research, particularly for inflammatory diseases. By combining neural and molecular data, InflammaSense enables faster, more cost-effective trials, reduces reliance on subjective self-reporting, and aligns with the FDA's trend toward biomarker-driven drug approvals, while also improving therapy use in critically ill patients.
Target Audience
The primary customers include pharmaceutical companies, biotech firms, government-funded research institutions, clinical researchers, defense agencies, and corporations focused on wellness programs.
Features
- Autonomic Neurography (ANG) monitoring provides real-time, objective physiological insights into a patient’s nervous system response to treatment.
- In-silico saliva and blood metabolite protein analysis enables early detection of treatment efficacy and objective measurement of drug impact on inflammation and stress markers.
- AI-driven biomarker technology for precise patient stratification and refined predictive model generation.
- Point-of-Care (PoC) biomarker technology facilitates faster and more reliable clinical trials.
- Wearable tech enables early detection and assessment of inflammatory diseases, mental health disorders, and cognitive overload.